RBC Capital lowered the firm’s price target on Argenx (ARGX) to $890 from $925 but keeps an Outperform rating on the shares after its Q4 results. The firm “remains buyers” given its expectations that Vyvgart’s uptake doubles from here in approved indications, adding it can’t think of many Biotech companies with 20 Phase II/III trials ongoing with relatively high probability of success, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target lowered to $890 from $925 at RBC Capital
- Argenx price target raised to $867 from $858 at Baird
- Argenx price target lowered to $1,120 from $1,160 at Guggenheim
- Argenx price target lowered to $1,247 from $1,317 at Wells Fargo
- Argenx price target raised to $940 from $915 at H.C. Wainwright